N-acetylcysteine in the quantity of 1200-1800 mg intravenously per day, 3 times decreased risk of death vs. the control group, 4 times decreased risk of mechanical ventilation vs. the control group and 4 times decreased risk of ICU admission vs. the control group, according to the clinical study disclosed in Sergey N. Avdeev et al., “N-acetylcysteine for the treatment of COVID-19 among hospitalized patients,” Journal of Infection, 09 July 2021, 84(1), 94-118, https://doi.org/10.1016/j.jinf.2021.07.003, JIF 38.637 (top 4% journals in Infectious Diseases).
N-acetylcysteine in the quantity of 600 mg per day for 14 days, 6 times decreased death from COVID-19 vs. the control group, according to the clinical study disclosed in Stelios F. Assimakopoulos et al., “N-acetyl-cysteine reduces the risk for mechanical ventilation and mortality in patients with COVID-19 pneumonia: a two-center retrospective cohort study,” Infectious Diseases, 29 June 2021, 53(11), 847-854, https://doi.org/10.1080/23744235.2021.1945675, JIF 5.838 (top 33% journals in Infectious Diseases).
NAC in the quantity of 2-30 mg/kg/day, given after the establishment of diabetes, may offer protection against the risk for stroke by altering both systemic and vascular prothrombotic responses, according to Bin Wang et al. “N-acetylcysteine attenuates systemic platelet activation and cerebral vessel thrombosis in diabetes,” Redox Biology, 14 (2018), 218-228, http://doi.org/10.1016/j.redox.2017.09.005, JIF 10.787 (top 9% journals in Biochemistry & Molecular Biology).
NAC is an effective and safe alternative to currently available antithrombotic agents to restore vessel patency after arterial occlusion, according to Sara Martinez de Lizarrondo et al. “Potent thrombolytic effect of N-Acetylcysteine on arterial thrombi,” Circulation, 2017, 136, 646-660, https://doi.org/10.1161/CIRCULATIONAHA.117.027290, JIF 39.922 (top 1.4% journals in Cardiac & Cardiovascular Systems and top 1.5% journals in Peripheral Vascular Disease).
Multiple Sclerosis (MS) is a neurological disorder associated with white and gray matter injury significantly due to autoimmune mediated inflammation processes. NAC positively affects cerebral glucose metabolism in MS patients, which is associated with qualitative, patient reported improvements in cognition and attention, according to Daniel A. Monti et al., “N-acetyl Cysteine Administration Is Associated With Increased Cerebral Glucose Metabolism in Patients With Multiple Sclerosis: An Exploratory Study,” Frontiers in Neurology, 14 February 2020, Volume 11, https://doi.org/10.3389/fneur.2020.00088, JIF 4.086 (top 35% journals in Clinical Neurology and top 43% journals in Neurosciences).